Focus Taiwan App
Download

Paxlovid treatment now eligible for postpartum women with COVID-19

05/23/2022 08:58 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

Postpartum women are now eligible to receive the oral antiviral drug Paxlovid as long as its use is approved by a doctor and the patient agrees, the Central Epidemic Command Center (CECC) said Monday.


(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

    We value your privacy.
    Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.
    172.30.142.75